Scholarlink

Summary <p>This study classifies osteoporotic patients treated in 16 FLS in Spain, evaluating therapeutic alignment with SEIOMM recommendations and imminent risk fracture. Findings indicate that 26.8% of patients are at very high-risk fracture, highlighting the need for better prescription practices for osteoanabolics. Fall prevention is pivotal in reducing new fractures.</p> Objective <p>To classify patients treated in 16 Fracture Liaison Services (FLS) in Spain according to high-risk fracture (HRF) and very high-risk fracture (VHRF) and evaluate the alignment of their pharmacological treatment with the Spanish Society for Bone and Mineral Metabolism Research (SEIOMM) guidelines. Additionally, we assessed the incidence of new fractures over a one-year follow-up period and analyzed associated risk factors.</p> Methods <p>This retrospective, multicenter, population-based observational cohort study included patients aged ≥ 50&#xa0;years with at least one fragility fracture in the preceding year. Data were collected from medical records from January 2015 to April 2024, capturing sociodemographic information, fracture characteristics, comorbidities, pharmacological treatments, and fall risk.</p> Results <p>Of 7161 patients, 1413 had one year of follow-up and sufficient baseline data for classification as either VHRF or HRF. Among these, 1034 (73.2%) were classified as HRF and 379 (26.8%) as VHRF. The median age was significantly higher in the VHRF group (76 vs. 72&#xa0;years in HRF; <i>p</i> &lt; 0.001). Pharmacological treatment was initiated in 86.5% of patients. Alendronate was predominantly prescribed for the HRF group, while parenteral treatments (zoledronate, denosumab) were more common in the VHRF group. During the first year, 84 patients (5.9%) experienced a new fracture, with 2 or more falls significantly associated with these subsequent fractures.</p> Conclusion <p>26.8% of patients were classified as VHRF. Treatment partially aligned with SEIOMM guidelines, though improved adherence to sequential osteoanabolic treatment is essential in VHRF patients. Fall prevention remains critical to reducing fracture recurrence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月12日

查看全文
  • M. J. Montoya-Garcia,
  • C. Carbonell-Abella,
  • M. Giner García,
  • B. Hernández-Cruz,
  • C. Gómez-Vaquero,
  • A. Naranjo,
  • R. Izquierdo Aviñó,
  • D. Mifsut Miedes,
  • A. P. Mozo Muriel,
  • J. Mora-Fernández,
  • S. Castro Oreiro,
  • D. Ovejero Crespo,
  • M. Jordà Llona,
  • C. Alvarado Escobar,
  • M. M. Femenías Sureda,
  • L. Cuadra-Llopart,
  • M. Mesa Ramos,
  • S. Santana Zorrilla,
  • D. Martínez-Laguna,
  • G. Martínez Díaz-Guerra,
  • J. M. Cancio-Trujillo,
  • Jesús Olmo,
  • Julia Barrera,
  • Mª Ángeles Vázquez-Gámez,
  • Jesús Bocio,
  • M. Ángel Rico,
  • M. Ángel Colmenero,
  • José Pérez Venegas,
  • Mª Luisa Serrano,
  • Manuela González Águila,
  • Lidia Valencia Muntalà,
  • Amparo Molina,
  • Soledad Ojeda,
  • Sonia Fuentes,
  • Leticia Cebollada Gadea,
  • Verónica Diaz Falcon,
  • María Carmen Martín Ballano,
  • Pilar Medrano Izquierdo,
  • Miriam Akasbi Montalvo yVirginia Pardo Guimerà,
  • María Teresa Navío Marco,
  • Leticia Lojo Oliveira,
  • Ana Salomé Pareja Martínez,
  • Angela Patricia Mozo Muriel,
  • María Rosalía De-Dios Álvarez,
  • Elia Cartagena Ruiz,
  • Marta Neira Álvarez y Brian Dax Vásquez Brolen,
  • Ricardo Larrainzar Garijo,
  • Ana Mª Moreno Morillo,
  • Eugenia Sopena,
  • Pilar Alamillo,
  • Rosa Mª San Segundo,
  • Sarai Angles,
  • Montserrat Fibla,
  • Xavier Nogués Solán,
  • Ana Isabel Silveria Moreno,
  • María del Pilar MárquezTorres,
  • Lourdes Cerezo Romero,
  • Elena Fernández Pons,
  • Aranzazu Ballester Suarez,
  • Virginia Gallart Úbeda,
  • Laura de Haro García,
  • Ana Isabel Silveria Moreno,
  • María del Pilar Márquez de Torres,
  • Lourdes Cerezo Romero,
  • José Luis Rodríguez García,
  • Marta Hernández Herrero

摘要

Summary

This study classifies osteoporotic patients treated in 16 FLS in Spain, evaluating therapeutic alignment with SEIOMM recommendations and imminent risk fracture. Findings indicate that 26.8% of patients are at very high-risk fracture, highlighting the need for better prescription practices for osteoanabolics. Fall prevention is pivotal in reducing new fractures.

Objective

To classify patients treated in 16 Fracture Liaison Services (FLS) in Spain according to high-risk fracture (HRF) and very high-risk fracture (VHRF) and evaluate the alignment of their pharmacological treatment with the Spanish Society for Bone and Mineral Metabolism Research (SEIOMM) guidelines. Additionally, we assessed the incidence of new fractures over a one-year follow-up period and analyzed associated risk factors.

Methods

This retrospective, multicenter, population-based observational cohort study included patients aged ≥ 50 years with at least one fragility fracture in the preceding year. Data were collected from medical records from January 2015 to April 2024, capturing sociodemographic information, fracture characteristics, comorbidities, pharmacological treatments, and fall risk.

Results

Of 7161 patients, 1413 had one year of follow-up and sufficient baseline data for classification as either VHRF or HRF. Among these, 1034 (73.2%) were classified as HRF and 379 (26.8%) as VHRF. The median age was significantly higher in the VHRF group (76 vs. 72 years in HRF; p < 0.001). Pharmacological treatment was initiated in 86.5% of patients. Alendronate was predominantly prescribed for the HRF group, while parenteral treatments (zoledronate, denosumab) were more common in the VHRF group. During the first year, 84 patients (5.9%) experienced a new fracture, with 2 or more falls significantly associated with these subsequent fractures.

Conclusion

26.8% of patients were classified as VHRF. Treatment partially aligned with SEIOMM guidelines, though improved adherence to sequential osteoanabolic treatment is essential in VHRF patients. Fall prevention remains critical to reducing fracture recurrence.